Catalyst Reports Q4 Revenue of $152.6M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy CPRX?
Reports Q4 revenue $152.6M, consensus $142.75M. "Our 2025 performance is a reflection of Catalyst's organic growth of our promoted products, FIRDAPSE and AGAMREE, and our continued commercial success. Achieving total revenues for 2025 of $589.0 million demonstrates the strength of our scalable business model and our continued dedication to patient care," said Rich Daly, President and CEO, Catalyst. "Looking forward, our core commercial capabilities and our exploration of lifecycle management opportunities within our portfolio will continue to create value. We also continue to execute our business development strategy, which includes recently widening our aperture to look at products in development that have an established proof of concept. Based on our recent progress and considering the growth opportunities that we see for both FIRDAPSE and AGAMREE, we anticipate 2026 will prove to be another exceptional year, as reflected in our 2026 revenue guidance."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.770
Low
33.00
Averages
34.00
High
35.00
Current: 24.770
Low
33.00
Averages
34.00
High
35.00
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Catalyst Pharmaceuticals Reports Record Revenues and Strong Growth Outlook for 2026
- Significant Revenue Growth: Catalyst Pharmaceuticals reported total revenues of $589 million for 2025, reflecting a 19.8% year-over-year increase that exceeded prior guidance, showcasing the company's strong market performance and strategic execution.
- Outstanding Product Performance: FIRDAPSE achieved net product revenue of $358.4 million, up 17% year-over-year, while AGAMREE saw a remarkable 67.5% increase, indicating an improving market penetration in therapeutic areas.
- Optimistic Future Outlook: Management set 2026 total revenue guidance between $615 million and $645 million, with FIRDAPSE expected to generate $435 million to $450 million, demonstrating confidence in sustained product growth.
- Strengthened Market Strategies: The company is aggressively advancing market penetration for FIRDAPSE and AGAMREE, particularly in idiopathic and cancer-associated LEMS, which is expected to further enhance market share and customer base.
See More
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook
- Halozyme Financial Performance: Halozyme's Q3 revenue increased by 22% year-over-year to $354 million, with earnings per share (EPS) soaring 36% to $1.43, demonstrating its strong market position in drug delivery systems.
- Catalyst Growth Potential: Catalyst achieved a remarkable 249% revenue growth leading up to 2024, with Q3 revenue rising 24% year-over-year to $436.3 million and EPS climbing 45.9% to $1.27, reflecting strong demand in rare disease treatments.
- Competitive Advantage: Both companies maintain low debt levels, with Halozyme reducing its long-term debt from $1.5 billion to $800 million, while Catalyst has no debt, providing them with greater flexibility for acquisitions and R&D investments.
- Optimistic Industry Outlook: The biotech sector rebounded in 2025, with the SPDR S&P Biotech ETF rising 27%, indicating a resurgence in market demand for innovative drugs, while both Halozyme and Catalyst are valued below the sector average, suggesting significant future growth potential.
See More
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth
- Biotech Recovery: In 2025, the SPDR S&P Biotech ETF surged 27%, nearly doubling the S&P 500's 16% gain, indicating a robust recovery in the biotech sector, supported by lower interest rates facilitating debt financing.
- Halozyme's Strong Growth: Halozyme Therapeutics saw its stock rise over 25% in the past year, with Q3 revenue increasing 22% year-over-year to $354 million and EPS jumping 36% to $1.43, showcasing its competitive edge in drug delivery systems.
- Catalyst's Profitability: Catalyst Pharmaceuticals reported a staggering 249% revenue growth from 2021 to 2024, with a 24% year-over-year increase in revenue to $436.3 million and a 45.9% rise in EPS to $1.27 this year, reflecting strong market demand in rare disease treatments.
- Optimistic Future Outlook: Halozyme forecasts annual revenue of $1.3 billion to $1.375 billion for 2026, representing 28% to 35% growth, while Catalyst anticipates revenue of $565 million to $585 million, nearly a 17% increase, indicating promising growth potential for both companies.
See More
Texas Instruments Maintains Hold Rating, Price Target Raised to $195
- Rating Maintenance and Price Target Increase: Truist Securities analyst William Stein maintained a Hold rating on Texas Instruments on December 19, raising the price target from $175 to $195, indicating confidence in the company's future performance despite a 0.3% drop in share price to $188.53 on Tuesday.
- Crane Company Acquisition Completed: Crane Company announced on January 5 that it has completed the acquisition of Precision Sensors & Instrumentation from Baker Hughes, which Cramer described as a “good” company, enhancing Crane's market position in the sensor field and driving future growth.
- Catalyst Pharmaceuticals Earnings Beat Expectations: Catalyst Pharmaceuticals reported third-quarter earnings of $0.68 per share on November 5, exceeding the analyst consensus of $0.33, with quarterly sales of $148.392 million surpassing estimates of $136.802 million, showcasing strong profitability and market demand.
- Market Reaction and Investment Outlook: Despite Catalyst Pharmaceuticals' share price falling 3.8% to $22.35 on Tuesday, Cramer remains optimistic about its future performance, suggesting the stock is inexpensive and may attract more investor interest.
See More
Texas Instruments Stock Performance Strong, Hold Recommended
- Hold Recommendation: Jim Cramer strongly advises investors to hold Texas Instruments stock, indicating its stability and growth potential in the market, reflecting confidence in the company's future performance.
- Company Evaluation: Cramer positively assesses Crane, labeling it a 'good company,' suggesting its competitiveness and sustainability in the industry, which may attract more investor interest.
- Catalyst Pharmaceuticals Praise: Cramer commends Catalyst Pharmaceuticals for having real earnings and being an inexpensive stock, indicating its potential in the biopharmaceutical sector, likely appealing to value investors.
- Investor Education: Cramer's investment guide and the registration information for the CNBC Investing Club aim to help investors invest smarter and enhance long-term wealth management capabilities, demonstrating a commitment to educating the market.
See More
Catalyst Pharmaceuticals Ranked 11th in Forbes' 2026 America's Most Successful Small-Cap Companies
- Industry Recognition: Catalyst Pharmaceuticals ranked 11th on Forbes' 2026 list of America's Most Successful Small-Cap Companies, highlighting its market position and influence in the rare disease treatment sector, which enhances the company's brand image.
- Performance Growth: The company achieved positive sales growth over the past year, reflecting its success in developing therapies for rare diseases and boosting investor confidence in its future prospects.
- Market Access: Catalyst focuses on providing innovative therapies for patients with rare diseases, ensuring they receive necessary treatments, which demonstrates the company's deep commitment to patient care and may enhance customer loyalty and market share.
- Strategic Expansion: Catalyst's strong presence in the U.S. market supports its global expansion strategy, as it continues to evaluate strategic opportunities to broaden its international footprint and enhance its competitive edge.
See More
Catalyst Pharmaceuticals Reports Record Revenues and Strong Growth Outlook for 2026
- Significant Revenue Growth: Catalyst Pharmaceuticals reported total revenues of $589 million for 2025, reflecting a 19.8% year-over-year increase that exceeded prior guidance, showcasing the company's strong market performance and strategic execution.
- Outstanding Product Performance: FIRDAPSE achieved net product revenue of $358.4 million, up 17% year-over-year, while AGAMREE saw a remarkable 67.5% increase, indicating an improving market penetration in therapeutic areas.
- Optimistic Future Outlook: Management set 2026 total revenue guidance between $615 million and $645 million, with FIRDAPSE expected to generate $435 million to $450 million, demonstrating confidence in sustained product growth.
- Strengthened Market Strategies: The company is aggressively advancing market penetration for FIRDAPSE and AGAMREE, particularly in idiopathic and cancer-associated LEMS, which is expected to further enhance market share and customer base.
See More
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook
- Halozyme Financial Performance: Halozyme's Q3 revenue increased by 22% year-over-year to $354 million, with earnings per share (EPS) soaring 36% to $1.43, demonstrating its strong market position in drug delivery systems.
- Catalyst Growth Potential: Catalyst achieved a remarkable 249% revenue growth leading up to 2024, with Q3 revenue rising 24% year-over-year to $436.3 million and EPS climbing 45.9% to $1.27, reflecting strong demand in rare disease treatments.
- Competitive Advantage: Both companies maintain low debt levels, with Halozyme reducing its long-term debt from $1.5 billion to $800 million, while Catalyst has no debt, providing them with greater flexibility for acquisitions and R&D investments.
- Optimistic Industry Outlook: The biotech sector rebounded in 2025, with the SPDR S&P Biotech ETF rising 27%, indicating a resurgence in market demand for innovative drugs, while both Halozyme and Catalyst are valued below the sector average, suggesting significant future growth potential.
See More
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth
- Biotech Recovery: In 2025, the SPDR S&P Biotech ETF surged 27%, nearly doubling the S&P 500's 16% gain, indicating a robust recovery in the biotech sector, supported by lower interest rates facilitating debt financing.
- Halozyme's Strong Growth: Halozyme Therapeutics saw its stock rise over 25% in the past year, with Q3 revenue increasing 22% year-over-year to $354 million and EPS jumping 36% to $1.43, showcasing its competitive edge in drug delivery systems.
- Catalyst's Profitability: Catalyst Pharmaceuticals reported a staggering 249% revenue growth from 2021 to 2024, with a 24% year-over-year increase in revenue to $436.3 million and a 45.9% rise in EPS to $1.27 this year, reflecting strong market demand in rare disease treatments.
- Optimistic Future Outlook: Halozyme forecasts annual revenue of $1.3 billion to $1.375 billion for 2026, representing 28% to 35% growth, while Catalyst anticipates revenue of $565 million to $585 million, nearly a 17% increase, indicating promising growth potential for both companies.
See More
Texas Instruments Maintains Hold Rating, Price Target Raised to $195
- Rating Maintenance and Price Target Increase: Truist Securities analyst William Stein maintained a Hold rating on Texas Instruments on December 19, raising the price target from $175 to $195, indicating confidence in the company's future performance despite a 0.3% drop in share price to $188.53 on Tuesday.
- Crane Company Acquisition Completed: Crane Company announced on January 5 that it has completed the acquisition of Precision Sensors & Instrumentation from Baker Hughes, which Cramer described as a “good” company, enhancing Crane's market position in the sensor field and driving future growth.
- Catalyst Pharmaceuticals Earnings Beat Expectations: Catalyst Pharmaceuticals reported third-quarter earnings of $0.68 per share on November 5, exceeding the analyst consensus of $0.33, with quarterly sales of $148.392 million surpassing estimates of $136.802 million, showcasing strong profitability and market demand.
- Market Reaction and Investment Outlook: Despite Catalyst Pharmaceuticals' share price falling 3.8% to $22.35 on Tuesday, Cramer remains optimistic about its future performance, suggesting the stock is inexpensive and may attract more investor interest.
See More
Texas Instruments Stock Performance Strong, Hold Recommended
- Hold Recommendation: Jim Cramer strongly advises investors to hold Texas Instruments stock, indicating its stability and growth potential in the market, reflecting confidence in the company's future performance.
- Company Evaluation: Cramer positively assesses Crane, labeling it a 'good company,' suggesting its competitiveness and sustainability in the industry, which may attract more investor interest.
- Catalyst Pharmaceuticals Praise: Cramer commends Catalyst Pharmaceuticals for having real earnings and being an inexpensive stock, indicating its potential in the biopharmaceutical sector, likely appealing to value investors.
- Investor Education: Cramer's investment guide and the registration information for the CNBC Investing Club aim to help investors invest smarter and enhance long-term wealth management capabilities, demonstrating a commitment to educating the market.
See More
Catalyst Pharmaceuticals Ranked 11th in Forbes' 2026 America's Most Successful Small-Cap Companies
- Industry Recognition: Catalyst Pharmaceuticals ranked 11th on Forbes' 2026 list of America's Most Successful Small-Cap Companies, highlighting its market position and influence in the rare disease treatment sector, which enhances the company's brand image.
- Performance Growth: The company achieved positive sales growth over the past year, reflecting its success in developing therapies for rare diseases and boosting investor confidence in its future prospects.
- Market Access: Catalyst focuses on providing innovative therapies for patients with rare diseases, ensuring they receive necessary treatments, which demonstrates the company's deep commitment to patient care and may enhance customer loyalty and market share.
- Strategic Expansion: Catalyst's strong presence in the U.S. market supports its global expansion strategy, as it continues to evaluate strategic opportunities to broaden its international footprint and enhance its competitive edge.
See More
